Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 980 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Disruptive Behavior Clear all
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

NCT05683249
View directory record Official record
Conditions
ADHD
Interventions
NRCT-101-SR, Placebo
Drug
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Garden Grove, California • Lakeland, Florida • Maitland, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
B-MPH
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
4 Years to 5 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children

NCT02712996
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Deficit Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
6 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 4, 2026, 5:35 PM EDT
Recruiting Phase 4 Interventional

Medication Treatment of ADHD in Pediatric Epilepsy

NCT07594652
View directory record Official record
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate hydrochloride (Jornay PM)
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Mental Health and School Performance in Urban Eighth Graders

NCT03906682
View directory record Official record
Conditions
Depressive Symptoms, Trauma, Psychological, Disruptive Behavior
Interventions
RAP Club, Healthy Topics
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
615 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD

NCT00418262
View directory record Official record
Conditions
Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Atomoxetine
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 11 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

NCT03006367
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Maitland, Florida • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Results available

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT01010750
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine Dimesylate (LDX), Immediate Release Mixed Amphetamine Salts (MAS-IR), LDX Placebo + MAS-IR Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 4, 2026, 5:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic, Brain Structure, and Environmental Effects on ADHD

NCT01721720
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
3 Years and older
Enrollment
1,091 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 1 Interventional

Training Executive, Attention and Motor Skills (TEAMS): Preliminary Studies

NCT01073176
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
TEAMS (Training Attention Executive and Motor Skills)
Other
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
4 Years to 5 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 1 Interventional

Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder

NCT02286817
View directory record Official record
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Adult Attention Deficit Hyperactivity Disorder

NCT01692782
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
SEP-225289, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Encino, California • Garden Grove, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2015 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 1 Interventional

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder

NCT04398225
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Centanafadine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Newport Beach, California • Marshfield, Massachusetts • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 4, 2026, 5:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

NCT04577417
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

NCT01114737
View directory record Official record
Conditions
Phenylketonuria
Interventions
Sapropterin dihydrochloride, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
8 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
26
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 4, 2026, 5:35 PM EDT
Completed No phase listed Observational

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Not applicable Interventional Results available

A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders

NCT03730194
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Sleep Disturbance
Interventions
Melatonin, Bedtime Bank
Dietary Supplement · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Not applicable Interventional

Early Intervention Foster Care: A Prevention Trial

NCT00701194
View directory record Official record
Conditions
School Readiness, Developmental Delays
Interventions
Early Intervention Foster Care (EIFC)
Behavioral
Lead sponsor
Oregon Social Learning Center
Other
Eligibility
3 Years to 6 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

NCT02777931
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
NFC-1, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Not applicable Interventional Results available

Pilot Feasibility Study of Neurofeedback for Attention Deficit Hyperactivity Disorder (ADHD)

NCT00886483
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Active Neurofeedback, Sham neurofeedback
Device
Lead sponsor
L. Eugene Arnold
Other
Eligibility
6 Years to 12 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Sep 4, 2026, 5:35 PM EDT
Completed Not applicable Interventional Results available

GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs

NCT01808066
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Pervasive Developmental Disorder, Asperger's Disorder
Interventions
Groundskeeper
Device
Lead sponsor
CogCubed, Corp
Industry
Eligibility
5 Years to 12 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 4, 2026, 5:35 PM EDT